Today: 13 June 2026
Browse Category

Stock Market 4 May 2026 - 5 May 2026

Micron Stock’s AI Memory Run Sends It Into U.S. Market-Cap Elite

Micron Stock’s AI Memory Run Sends It Into U.S. Market-Cap Elite

Micron Technology shares traded at $576.45 premarket Tuesday, valuing the company at about $658.3 billion. Fiscal Q2 revenue reached $23.86 billion, with net income of $13.79 billion, as demand for high-bandwidth memory in AI data centers surged. DRAM and NAND sales jumped on sharp price increases, but the company warned of potential margin risks if demand slows. Micron plans to exit its consumer memory business by February 2026.
5 May 2026
···
CRWV Stock Jumps Before Earnings: Why Meta’s $21 Billion AI Deal Has Wall Street Watching

CRWV Stock Jumps Before Earnings: Why Meta’s $21 Billion AI Deal Has Wall Street Watching

CoreWeave shares climbed 5.4% to $125.43 in premarket trading Tuesday after Meta committed about $21 billion for cloud capacity through 2032. Jefferies estimates recent contracts could lift CoreWeave’s backlog above $95 billion, up from $66.8 billion at year-end. The company reports first-quarter results Thursday. CoreWeave posted a $1.17 billion net loss in 2025 on $5.13 billion in revenue.
5 May 2026
····
Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer posted first-quarter adjusted earnings of 75 cents per share on $14.45 billion in revenue, beating Wall Street forecasts. Sales of Eliquis and Padcev rose, offsetting steep declines in COVID products. The company maintained its 2026 revenue and profit outlook. Research and development expenses increased 12% as Pfizer invested in oncology and obesity drugs.
5 May 2026
···
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 05.05.2026

LIVEMarkets rolling coverageStarted: May 5, 2026, 12:00 AM EDTUpdated: May 5, 2026, 11:59 PM EDT Macmahon Holdings Drives Growth Among Top ASX Penny Stocks May 5, 2026, 11:51 PM EDT. The Australian market shows signs of a rebound, influenced by positive Wall Street trends and lower Brent crude prices. Macmahon Holdings (ASX:MAH) stands out among penny stocks, with a market cap of A$1.6 billion and nearly A$2 billion in mining revenue. The company secured a major five-year, A$190 million contract for the Wonawinta Silver project, boosting its earnings 97.2% over the past year. Despite a relatively new board, Macmahon's inclusion
5 May 2026
·
Dow Drops 557 Points as Oil Shock Hits US Stocks; Palantir Slides After Hours

Dow Drops 557 Points as Oil Shock Hits US Stocks; Palantir Slides After Hours

The Dow Jones Industrial Average fell 1.13%, dropping over 550 points, as a surge in oil prices linked to Iranian attacks in the Strait of Hormuz rattled markets. Brent crude jumped 5.8% to $114.44 a barrel. Ten of 11 S&P 500 sectors declined, with energy the exception. Palantir shares slipped 2.69% after hours despite raising its 2026 revenue forecast and posting strong quarterly results.
5 May 2026
··
Firefly Aerospace Stock Jumps After Q1 Revenue Beat and Golden Dome Defense Deal

Firefly Aerospace Stock Jumps After Q1 Revenue Beat and Golden Dome Defense Deal

Firefly Aerospace shares jumped 10% in after-hours trading Monday after reporting record first-quarter revenue of $80.9 million, up 40% from the prior quarter. The company kept its 2026 revenue outlook and said its SciTec unit won a U.S. Space Force contract for the Space-Based Interceptor program. Firefly’s net loss widened to $96.7 million, but its adjusted loss beat analyst estimates.
5 May 2026
···
Sterling Infrastructure Stock Jumps as Data-Center Work Drives Q1 Beat, 2026 Outlook Raise

Sterling Infrastructure Stock Jumps as Data-Center Work Drives Q1 Beat, 2026 Outlook Raise

Sterling Infrastructure shares jumped 19% in late trading Monday after first-quarter profit and revenue beat estimates and the company raised its 2026 outlook. Net income was $96 million on revenue of $825.7 million, with E-Infrastructure revenue up 174% to $597.7 million. Backlog reached $3.80 billion, up 78% from a year ago. Building Solutions adjusted operating income fell 42% amid continued housing market weakness.
5 May 2026
···
Stock Market Today: Dow Sinks 557 Points as Oil Shock Tests Wall Street’s Record Run

Stock Market Today: Dow Sinks 557 Points as Oil Shock Tests Wall Street’s Record Run

U.S. stocks fell Monday, with the S&P 500 down 0.4% and the Dow losing 557 points, after oil prices surged and fighting resumed near the Strait of Hormuz. Brent crude jumped 5.8% to $114.44 a barrel after the UAE reported an Iranian attack. The U.S. military said it sank six boats targeting civilian ships in the area. FedEx and UPS shares dropped over 9% after Amazon announced new supply chain services.
5 May 2026
·
Pinterest Stock Surges After Q1 Earnings Beat as AI Ad Push Lifts Revenue Outlook

Pinterest Stock Surges After Q1 Earnings Beat as AI Ad Push Lifts Revenue Outlook

Pinterest shares jumped 15% to $24.06 in after-hours trading after first-quarter revenue beat estimates and the company issued a strong second-quarter outlook. Revenue rose 18% to $1.008 billion, with global monthly active users up 11% to 631 million. The quarter saw a net loss of $73.6 million, but adjusted earnings reached 27 cents per share, topping forecasts. Pinterest cited ongoing economic and regulatory risks in its outlook.
4 May 2026
····
Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus

Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus

Lunai Bioworks issued $20 million in Series B preferred stock to acquire Neurobridge IP Holdings’ CNS drug-delivery and neurotherapeutic patents, closing the deal May 1. The company said the transaction lifts its stockholders’ equity above Nasdaq’s $2.5 million listing minimum. Lunai shares traded at $0.3246 Monday, leaving its market value at $7.6 million. The acquired assets consist solely of patents, with no cash paid.
4 May 2026
···
Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio shares surged 32% after the company reported early results from its cell-therapy trial and priced a $150 million stock offering with participation from Eli Lilly and others. Two of four pemphigus vulgaris patients showed clinical activity with rese-cel, its experimental CAR-T therapy. The company expects to fund operations into mid-2027. New data will be presented at the ASGCT meeting on May 14.
4 May 2026
····
Union Pacific’s $85 Billion Norfolk Southern Merger Faces a New Walk-Away Test

Union Pacific’s $85 Billion Norfolk Southern Merger Faces a New Walk-Away Test

Union Pacific warned it could drop its $85 billion bid for Norfolk Southern if U.S. regulators require major line sales or trackage rights as merger conditions. The Surface Transportation Board is still reviewing whether the revised application is complete, with a May 8 deadline for comments. CSX and other rivals have stepped up opposition, citing reduced competition. Union Pacific may owe Norfolk Southern a $2.5 billion fee if it walks away.
4 May 2026
··
Above Food Ingredients (ABVE) Stock Jumps as Delayed 20-F Filing Keeps Investors on Edge

Above Food Ingredients (ABVE) Stock Jumps as Delayed 20-F Filing Keeps Investors on Edge

Above Food Ingredients shares surged about 22% to $0.65 in heavy Nasdaq trading Monday, with volume topping 42 million shares. The rally came as the company’s fiscal 2025 annual report remained delayed due to an ongoing audit. Above Food last reported a net loss of $53.3 million and a working-capital deficit of $85.4 million. Peer food and ingredient stocks moved little by comparison.
4 May 2026
··
Cenovus Energy Stock Climbs Before Q1 Results as CIBC Puts MEG Deal in Focus

Cenovus Energy Stock Climbs Before Q1 Results as CIBC Puts MEG Deal in Focus

Cenovus Energy shares climbed 2.9% to C$40.96 in Toronto after CIBC Capital Markets reaffirmed an outperformer rating and set a C$46 target ahead of first-quarter results. CIBC estimated quarterly production at 962,000 barrels of oil equivalent per day and projected cash flow per share of C$1.63, above consensus. Cenovus will report results May 6, its first full quarter including former MEG Energy assets.
4 May 2026
···
1 … 135 136 137 138 139 … 1,549

Stock Market Today

  • Ascletis Pharma Stock Falls 41.6% in a Month, Valuation Mixed Amid Losses
    June 13, 2026, 12:37 AM EDT. Ascletis Pharma (SEHK:1672) shares dropped 4.4% last week and 41.6% over the past month, raising questions about its valuation. The stock trades at a price-to-book (P/B) ratio of 4.7x, above the Hong Kong Biotech sector average of 3.2x but below a peer group average of 12.5x, signaling mixed valuation metrics. The company remains unprofitable with a negative return on equity of 18.61%, making earnings-based measures less relevant. While longer-term returns remain positive, recent revenue and net income weaknesses alongside ongoing losses pose risks. Investors are advised to review underlying data carefully before deciding on Ascletis Pharma's stock prospects amid a cautious market sentiment.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Go toTop